Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mCALR DAC
- Development stage
- Preclinical
- Lead developer
- Prelude Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
mCALR DAC is a preclinical-stage mutated calreticulin (mCALR)-targeted degrader antibody conjugate (DAC) being developed by Prelude Therapeutics for the treatment of CALR-mutated myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF). The therapeutic approach utilizes a monoclonal antibody targeting mutated calreticulin, a neoantigen selectively presented on the cell surface of malignant myeloid cells, conjugated to a proprietary targeted protein degradation payload (such as a CDK9 degrader or SMARCA2/4 degrader). By delivering the degrader payload directly to mCALR-positive cells, the conjugate selectively eliminates malignant clones while sparing healthy hematopoietic cells, offering a potentially disease-modifying therapy with an improved therapeutic index.
- Other names
- mCALR-targeted DACmCALR-targeted degrader antibody conjugatemCALR x CDK9 DACmCALR x SMARCA2/4 DACmutated calreticulin degrader antibody conjugate
02
Targets
CDK9 (Cyclin-dependent kinase 9)CALR mutant (Calreticulin Mutant Protein)
Beyond the preview
Go deeper on mCALR DAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mCALR DAC.